China Recombinant Human Endostatin Investigation Market Report, 2019-2023 - ResearchAndMarkets.com

DUBLIN--()--The "Investigation Report on China's Recombinant Human Endostatin Market, 2019-2023" report has been added to ResearchAndMarkets.com's offering.

In 2017, the number of lung cancer patients in China rose to 800,000; 700,000 people died of lung cancer, accounting for over 20% of the cancer deaths in China. The incidence of lung cancer is growing at an annual rate of more than 20%. It is expected that in 2025, lung cancer will kill nearly 1 million people in China. In 2017, the number of lung cancer patients in China and the number of people who died of lung cancer in China both accounted for 40% of the global total. And about 80% of the lung cancer patients had non-small cell lung cancer (NSCLC).

Recombinant Human Endostatin, an angiogenesis inhibitor, was developed by a Chinese enterprise in 1999 and approved by the China Food and Drug Administration (CFDA) in 2005 to be used in the combination chemotherapy for the recurrence and metastasis of NSCLC. Recombinant Human Endostatin acts on vascular endothelial cells to inhibit the movement of endothelial cells that form blood vessels and the formation of tumor angiogenesis and block the nutrition supply to tumor cells. In this way, it inhibits tumor proliferation or metastasis.

The sales value of Recombinant Human Endostatin increased sharply after it was launched in China. It rose from CNY 148 million in 2013 to CNY 272 million in 2017, representing a CAGR of 16.47%.

By Aug. 2019, only one enterprise's Recombinant Human Endostatin has been approved to be sold in China. In the context of worsening environmental pollution and over 300 million smokers, the number of lung cancer patients in China will continue to increase in the next few years. Therefore, the market size of Recombinant Human Endostatin will keep expanding and more enterprises will launch their Recombinant Human Endostatin products in China.

Topics covered:

  • Incidence of lung cancer in China
  • Status of China's Recombinant Human Endostatin market
  • Prices of Recombinant Human Endostatin in China
  • Development trends of Recombinant Human Endostatin in China

Key Topics Covered:

1 Relevant Concepts of Recombinant Human Endostatin

1.1 Indications for Recombinant Human Endostatin

1.2 Development of Recombinant Human Endostatin in China

1.3 Patents and Government Approval on Recombinant Human Endostatin in China

2 Sales of Recombinant Human Endostatin in China, 2013-2017

2.1 Sales Value

2.2 Sales volume

2.3 Sales of Recombinant Human Endostatin by Dosage Form in China, 2013-2017

3 Analysis of Major Manufacturers of Recombinant Human Endostatin in China, 2013-2017

3.1 Analysis on Market Share of Major Manufacturers of Recombinant Human Endostatin

3.2 Yantai Medgenn Co., Ltd.

4 Prices of Recombinant Human Endostatin in China, 2017-2018

4.1 Yantai Medgenn Co., Ltd. (Endostar)

4.2 Analysis of Potential Competitors

5 Prospect of China's Recombinant Human Endostatin Market, 2019-2023

5.1 Factors Influencing Development of China's Recombinant Human Endostatin Market

5.1.1 Driving Forces and Market Opportunities

5.1.2 Threats and Challenges

5.2 Forecast on Market Size

5.3 Forecast on Market Trend

For more information about this report visit https://www.researchandmarkets.com/r/b8jlkp

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900